Sarcoidosis associated with pembrolizumab alone or in combination with chemotherapy agents: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)

被引：0
|
作者：
Pawar, Mansi [1 ]
Lukose, Lipin [1 ]
Viswam, Subeesh K. [2 ]
Salim, Mohammed K. T. [3 ]
机构：
[1] Manipal Coll Pharmaceut, Manipal, India
[2] Cactus Communicat Private Ltd, Cactus Life Sci, Mumbai, Maharashtra, India
[3] Manipal Acad Higher Educ, Dept Pharm Practice, Manipal Coll Pharmaceut Sci, Manipal, India
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：639 / 639
页数：1
相关论文
共 50 条
  • [21] Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS)
    Ying Zhao
    Jingru Zhang
    Kai Zheng
    Sydney Thai
    Ross J. Simpson
    Alan C. Kinlaw
    Yang Xu
    Jingkai Wei
    Xiangli Cui
    John B Buse
    Til Stürmer
    Tiansheng Wang
    Drugs - Real World Outcomes, 2022, 9 : 231 - 241
  • [22] Melanoma associated with TNFa inhibitor agents in the FDA Adverse Event Reporting System (FAERS): Analysis of reported outcomes
    Nardone, Beatrice
    Bhattacharya, Tanya
    Bruins, Finola M.
    Hammel, Josh A.
    Haugh, Isabel M.
    West, Dennis P.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB209 - AB209
  • [23] Hypoglycemia Associated with Antibiotics Alone and in Combination with Sulfonylureas and Meglitinides: An Epidemiologic Surveillance Study of the FDA Adverse Event Reporting System (FAERS)
    Kaitlin E. Kennedy
    Chengwen Teng
    Taylor M. Patek
    Christopher R. Frei
    Drug Safety, 2020, 43 : 363 - 369
  • [24] Hypoglycemia Associated with Antibiotics Alone and in Combination with Sulfonylureas and Meglitinides: An Epidemiologic Surveillance Study of the FDA Adverse Event Reporting System (FAERS)
    Kennedy, Kaitlin E.
    Teng, Chengwen
    Patek, Taylor M.
    Frei, Christopher R.
    DRUG SAFETY, 2020, 43 (04) : 363 - 369
  • [25] A pharmacovigilance analysis of abrocitinib-related skin adverse events based on the FDA Adverse Event Reporting System (FAERS)
    Huang, Min
    Li, Peng
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2025, 317 (01)
  • [26] Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
    He, Chang-Zhu
    Qiu, Qin
    Lu, Song-Jie
    Xue, Fu-Li
    Liu, Jun-Qiao
    He, Yu
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [27] Romosozumab adverse event profile: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) from 2019 to 2023 Response
    Guldan, Mustafa
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2025, 37 (01)
  • [28] Compartment syndrome associations with drugs: a pharmacovigilance study of the FDA adverse event reporting system (FAERS)
    Kong, Wenqiang
    Shu, Yunfeng
    Tang, Juan
    Wan, Jie
    Yang, Xueting
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [29] A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) for gemcitabine
    Zhang, Cheng
    Li, Ke
    Xu, Shu-Ning
    Qiao, Lei
    Ren, Yu-Lin
    Li, Qun
    Liu, Ying
    EXPERT OPINION ON DRUG SAFETY, 2025, 24 (03) : 365 - 376
  • [30] Adverse events associated with acute pancreatitis caused by immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database
    Tong, Lihua
    Yuan, Yanling
    He, Wanming
    Yang, Wen
    Pan, Xingxi
    EXPERT OPINION ON DRUG SAFETY, 2025,
12345